Last Updated : December 1, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Xarelto | Rivaroxaban | List with clinical criteria and/or conditions | Complete | |||
| Ibrance | Palbociclib | Withdrawn | ||||
| Adcetris | Brentuximab vedotin | Withdrawn | ||||
| Cyramza | Ramucirumab | Cancelled | ||||
| Venclexta | Venetoclax | Withdrawn | ||||
| Admelog | Insulin lispro | Cancelled | ||||
| Erbitux | Cetuximab | Cancelled | ||||
| Translarna | ataluren | Cancelled | ||||
| TBD | Rituximab | Cancelled | ||||
| TBD | Trastuzumab | Cancelled |
Last Updated : December 1, 2023